Delcath Systems, Inc. announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.
Total revenue for the fourth quarter and full year is expected to be approximately $20.7 million and $85.2 million, respectively.
The company's key products, HEPZATO KIT and CHEMOSAT, contributed significantly to the revenue growth.
Revenue Breakdown
HEPZATO KIT contributed approximately $19.0 million in the fourth quarter and $78.8 million in the full year, while CHEMOSAT added around $1.7 million in the fourth quarter and $6.4 million for the full year.
Share Buyback Program
628,572 common shares were repurchased for $6.0 million by December 31, 2025, under the approved $25.0 million Share Buyback Program.
Financial Position
As of December 31, 2025, Delcath had approximately $91.0 million in cash and short-term investments with no debt, reflecting a strong financial position.
- Delcath reported significant revenue growth in 2025 driven by the performance of their key products, HEPZATO KIT and CHEMOSAT.
- The company's financial position improved with $91.0 million in cash and short-term investments by the end of 2025, indicating financial stability and growth potential.
Delcath's strong financial results and business performance in 2025 position the company for continued growth and expansion in 2026.